erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.
"our protocol says if you are suspicious for lyme disease, you start treating", said rusk..
.
biohaven: "rimegepant pivotal phase 3 trial results -- conference call.".